Hip & pelvis

  • 제36권1호
  • /
  • Pages.1-11
  • /
  • 2024
  • /
  • 2287-3260(pISSN)
  • /
  • 2287-3279(eISSN)
대한고관절학회 (The Korean Hip Society)
권호 표지
DOI QR코드

DOI QR Code

Pathophysiology and Treatment of Gout Arthritis; including Gout Arthritis of Hip Joint: A Literature Review

  • Yonghan Cha (Department of Orthopedic Surgery, Daejeon Eulji Medical Center, Eulji University School of Medicine) ;
  • Jongwon Lee (Department of Orthopedic Surgery, Daejeon Eulji Medical Center, Eulji University School of Medicine) ;
  • Wonsik Choy (Department of Orthopedic Surgery, Daejeon Eulji Medical Center, Eulji University School of Medicine) ;
  • Jae Sun Lee (Advanced Therapy Center, Catholic Kwandong University International St. Mary's Hospital, College of Medicine, Catholic Kwandong University) ;
  • Hyun Hee Lee (Department of Orthopedic Surgery, Catholic Kwandong University International St. Mary's Hospital, College of Medicine, Catholic Kwandong University) ;
  • Dong-Sik Chae (Department of Orthopedic Surgery, Catholic Kwandong University International St. Mary's Hospital, College of Medicine, Catholic Kwandong University)
  • 투고 : 2023.06.29
  • 심사 : 2023.08.10
  • 발행 : 2024.03.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Gout is triggered by the accumulation of uric acid in the body, leading to hyperuricemia. Genetic, metabolic, and environmental factors can influence this condition. Excessive uric acid buildup results in the formation of monosodium urate (MSU) crystals, which precipitate in specific areas of the body, including the joints, where they can cause symptoms of gout. While the acute and chronic symptoms of gout have been well-documented, diagnosis of gout affecting the hip joint poses significant challenges. The global incidence of gout, the most prevalent form of inflammatory arthritis, is on the rise. Evaluation of the clinical signs, laboratory results, and imaging results is generally required for diagnosis of gout in cases where MSU crystals have not been detected. Hyperuricemia is considered a primary cause of arthritis symptoms, and comprehensive guidelines for treatment are available. Therefore, the choice of medication is straightforward, and moderate effectiveness of treatment has been demonstrated. Gout is a chronic disease, requiring lifelong uric acid-lowering medications, thus application of a treatment strategy based on the target blood uric acid concentration is necessary. Consequently, cases of gout will likely be observed more frequently by hip surgeons in clinical scenarios in the future. The objective of this review is to provide an overview of the pathophysiology of gout and subsequently examine recent advances in diagnostic methods and therapeutic agents based on an understanding of its underlying mechanisms. In addition, literature on gout-related issues affecting the hip joint, providing a useful reference for hip surgeons is examined.

키워드

과제정보

This review article was presented at the Clinical Practice Guidelines Symposium of the Korean Hip Society on May 13, 2023.

참고문헌

  1. Clebak KT, Morrison A, Croad JR. Gout: rapid evidence review. Am Fam Physician. 2020;102:533-8.
  2. Kim Y, Oh HC, Park JW, et al. Diagnosis and treatment of inflammatory joint disease. Hip Pelvis. 2017;29:211-22. https://doi.org/10.5371/hp.2017.29.4.211
  3. Roddy E. Revisiting the pathogenesis of podagra: why does gout target the foot? J Foot Ankle Res. 2011;4:13. https://doi.org/10.1186/1757-1146-4-13
  4. Galozzi P, Bindoli S, Doria A, Oliviero F, Sfriso P. Autoinflammatory features in gouty arthritis. J Clin Med. 2021;10:1880. https://doi.org/10.3390/jcm10091880
  5. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388:2039-52. https://doi.org/10.1016/s0140-6736(16)00346-9
  6. Ragab G, Elshahaly M, Bardin T. Gout: an old disease in new perspective - a review. J Adv Res. 2017;8:495-511. https://doi.org/10.1016/j.jare.2017.04.008
  7. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11:649-62. https://doi.org/10.1038/nrrheum.2015.91
  8. Kamei K, Konta T, Hirayama A, et al. A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol Dial Transplant. 2014;29:2286-92. https://doi.org/10.1093/ndt/gfu256
  9. McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452-60. https://doi.org/10.7326/0003-4819-54-3-452
  10. Emmerson BT. The management of gout. N Engl J Med. 1996;334:445-51. https://doi.org/10.1056/nejm199602153340707
  11. Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2015;77:323-45. https://doi.org/10.1146/annurev-physiol-021113-170343
  12. Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3:764. https://doi.org/10.1038/ncomms1756
  13. Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol. 2005;9:195-205. https://doi.org/10.1007/s10157-005-0368-5
  14. Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009;5:e1000504. https://doi.org/10.1371/journal.pgen.1000504
  15. Phipps-Green AJ, Merriman ME, Topless R, et al. Twentyeight loci that influence serum urate levels: analysis of association with gout. Ann Rheum Dis. 2016;75:124-30. https://doi.org/10.1136/annrheumdis-2014-205877
  16. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis. 1998;57:509-10. https://doi.org/10.1136/ard.57.9.509
  17. Kanbara A, Seyama I. Effect of urine pH on uric acid excretion by manipulating food materials. Nucleosides Nucleotides Nucleic Acids. 2011;30:1066-71. https://doi.org/10.1080/15257770.2011.596498
  18. Towiwat P, Li ZG. The association of vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and gout. Int J Rheum Dis. 2015;18:495-501. https://doi.org/10.1111/1756-185x.12622
  19. Desai J, Steiger S, Anders HJ. Molecular pathophysiology of gout. Trends Mol Med. 2017;23:756-68. https://doi.org/10.1016/j.molmed.2017.06.005
  20. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312-24. https://doi.org/10.1136/ard.2006.055269
  21. Hamburger M, Baraf HS, Adamson TC 3rd, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123(6 Suppl 1):3-36. https://doi.org/10.3810/pgm.2011.11.2511
  22. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73:328-35. https://doi.org/10.1136/annrheumdis-2013-203325
  23. Graf SW, Whittle SL, Wechalekar MD, et al. Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative. Int J Rheum Dis. 2015;18:341-51. https://doi.org/10.1111/1756-185x.12557
  24. Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74:1789-98. https://doi.org/10.1136/annrheumdis-2015-208237 Erratum in: Ann Rheum Dis. 2016;75:473. https://doi.org/10.1136/annrheumdis2015-208237corr1
  25. Multi-Disciplinary Expert Task Force on Hyperuricemia and Its Related Diseases. [Chinese multi-disciplinary consensus on the diagnosis and treatment of hyperuricemia and its related diseases]. Zhonghua Nei Ke Za Zhi. 2017;56:235-48. Chinese. https://doi.org/10.3760/cma.j.issn.0578-1426.2017.03.021
  26. Qaseem A, McLean RM, Starkey M, et al. Diagnosis of acute gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166:52-7. https://doi.org/10.7326/m16-0569
  27. Qaseem A, Harris RP, Forciea MA, et al. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166:58-68. https://doi.org/10.7326/m16-0570
  28. Meyers OL, Cassim B, Mody GM. Hyperuricaemia and gout: clinical guideline 2003. S Afr Med J. 2003;93(12 Pt 2):961-71.
  29. Manara M, Bortoluzzi A, Favero M, et al. Italian Society of Rheumatology recommendations for the management of gout. Reumatismo. 2013;65:4-21. https://doi.org/10.4081/reumatismo.2013.4
  30. Yamanaka H; Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30:1018-29. https://doi.org/10.1080/15257770.2011.596496
  31. Ministry of Health Malaysia. Management of gout [Internet]. Ministry of Health Malaysia; 2021 Nov [cited 2023 Jul 1]. Available from: https://www.moh.gov.my/moh/resources/Penerbitan/CPG/Rheumatology/e-CPG_Management_of_Gout_(Second_Edition).pdf
  32. Sivera F, Andres M, Falzon L, van der Heijde DM, Carmona L. Diagnostic value of clinical, laboratory, and imaging findings in patients with a clinical suspicion of gout: a systematic literature review. J Rheumatol Suppl. 2014;92:3-8. https://doi.org/10.3899/jrheum.140456
  33. Zhang Q, Gao F, Sun W, Ma J, Cheng L, Li Z. The diagnostic performance of musculoskeletal ultrasound in gout: a systematic review and meta-analysis. PLoS One. 2018;13:e0199672. https://doi.org/10.1371/journal.pone.0199672
  34. Yu Z, Mao T, Xu Y, et al. Diagnostic accuracy of dual-energy CT in gout: a systematic review and meta-analysis. Skeletal Radiol. 2018;47:1587-93. https://doi.org/10.1007/s00256-018-2948-y
  35. Roddy E, Clarkson K, Blagojevic-Bucknall M, et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann Rheum Dis. 2020;79:276-84. https://doi.org/10.1136/annrheumdis-2019-216154
  36. Rainer TH, Cheng CH, Janssens HJ, et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med. 2016;164:464-71. https://doi.org/10.7326/M14-2070
  37. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020;72:879-95. https://doi.org/10.1002/art.41247 Erratum in: Arthritis Rheumatol. 2021;73:413. https://doi.org/10.1002/art.41688
  38. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63:2226-37. https://doi.org/10.1002/art.30389 Erratum in: Arthritis Rheum. 2011;63:3521.
  39. Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review. Rheumatology (Oxford). 2006;45:1422-31. https://doi.org/10.1093/rheumatology/kel071
  40. Schumacher HR, Berger MF, Li-Yu J, Perez-Ruiz F, Burgos-Vargas R, Li C. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. J Rheumatol. 2012;39:1859-66. https://doi.org/10.3899/jrheum.110916
  41. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29-42. https://doi.org/10.1136/annrheumdis-2016-209707
  42. Yamanaka H, Tamaki S, Ide Y, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018;77:270-6. https://doi.org/10.1136/annrheumdis-2017-211574
  43. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429-32.
  44. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63. https://doi.org/10.1186/ar2978
  45. Kim JW, Kwak SG, Park SH. Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database. Korean J Intern Med. 2018;33:228-9. https://doi.org/10.3904/kjim.2016.429
  46. Pillinger MH, Mandell BF. Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum. 2020;50(3S):S24-30. https://doi.org/10.1016/j.semarthrit.2020.04.010
  47. Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76:1522-8. https://doi.org/10.1136/annrheumdis-2016-210872
  48. Son CN, Stewart S, Su I, Mihov B, Gamble G, Dalbeth N. Global patterns of treat-to-serum urate target care for gout: systematic review and meta-analysis. Semin Arthritis Rheum. 2021;51:677-84. https://doi.org/10.1016/j.semarthrit.2021.04.011 Erratum in: Semin Arthritis Rheum. 2022;52:151929. https://doi.org/10.1016/j.semarthrit.2021.12.001
  49. Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396:1745-57. https://doi.org/10.1016/S0140-6736(20)32234-0
  50. Pascart T, Latourte A, Flipo RM, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine. 2020;87:395-404. https://doi.org/10.1016/j.jbspin.2020.05.002
  51. Chung WK, Slater GL, Bates EH. Treatment of septic arthritis of the hip by arthroscopic lavage. J Pediatr Orthop. 1993;13:444-6. https://doi.org/10.1097/01241398-199307000-00005
  52. Hadler NM, Franck WA, Bress NM, Robinson DR. Acute polyarticular gout. Am J Med. 1974;56:715-9. https://doi.org/10.1016/0002-9343(74)90639-1
  53. Huang Y, Huang J, Luo C, Chen L, Huang B. Treatment of atypical gouty arthritis of the hip using total hip arthroplasty: a case report. Medicine (Baltimore). 2020;99:e23027. https://doi.org/10.1097/MD.0000000000023027
  54. Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis. 2010;69:1907-12. https://doi.org/10.1136/ard.2010.128454
  55. Pascual E, Sivera F, Andres M. Synovial fluid analysis for crystals. Curr Opin Rheumatol. 2011;23:161-9. https://doi.org/10.1097/BOR.0b013e328343e458
  56. Zhu L, Zheng S, Wang W, Zhou Q, Wu H. Combining hyperechoic aggregates and the double-contour sign increases the sensitivity of sonography for detection of monosodium urate deposits in gout. J Ultrasound Med. 2017;36:935-40. https://doi.org/10.7863/ultra.16.03046
  57. Di Matteo A, Filippucci E, Cipolletta E, et al. Ultrasound and clinical features of hip involvement in patients with gout. Joint Bone Spine. 2019;86:633-6. https://doi.org/10.1016/j.jbspin.2019.01.027
  58. Xu S, Emanuelli E, Tarakemeh A, Vopat BG, Schroeppel JP, Mullen S. Gout presenting as acute hip pain in a young woman: a case report. JBJS Case Connect. 2019;9:e11. https://doi.org/10.2106/JBJS.CC.18.00164
  59. Tolin MC, Navarra SV. Severe hip and knee pain in a man with chronic tophaceous gout. Int J Rheum Dis. 2009;12:57-60. https://doi.org/10.1111/j.1756-185X.2009.01385.x
  60. Shah L, Zywiciel J, Kui A, et al. Adverse reaction to metal debris with accompanying gout and amyloid deposits in hip arthroplasty. Radiol Case Rep. 2023;18:1005-9. https://doi.org/10.1016/j.radcr.2022.11.079
  61. Parisien RL, Ment A, Shin M, Anand N, Martin EA. Pathologic hip fracture by virtue of a rare osseous manifestation of gout: a case report. JBJS Case Connect. 2020;10:e20.00231. https://doi.org/10.2106/JBJS.CC.20.00231
  62. Braun T, Schett G. Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep. 2012;10:101-8. https://doi.org/10.1007/s11914-012-0104-5
  63. Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y. IL-1 plays an important role in the bone metabolism under physiological conditions. Int Immunol. 2010;22:805-16. https://doi.org/10.1093/intimm/dxq431
  64. Chen W, Roncal-Jimenez C, Lanaspa M, et al. Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo. Metabolism. 2014;63:150-60. https://doi.org/10.1016/j.metabol.2013.09.018
  65. Hui JY, Choi JW, Mount DB, Zhu Y, Zhang Y, Choi HK. The independent association between parathyroid hormone levels and hyperuricemia: a national population study. Arthritis Res Ther. 2012;14:R56. https://doi.org/10.1186/ar3769
  66. Paik JM, Kim SC, Feskanich D, Choi HK, Solomon DH, Curhan GC. Gout and risk of fracture in women: a prospective cohort study. Arthritis Rheumatol. 2017;69:422-8. https://doi.org/10.1002/art.39852
  67. Kim SC, Paik JM, Liu J, Curhan GC, Solomon DH. Gout and the risk of non-vertebral fracture. J Bone Miner Res. 2017;32:230-6. https://doi.org/10.1002/jbmr.2978